The litigation concerns shares purchased between December 17, 2025, and July 26, 2026. According to the court filing, Capricor failed to secure FDA approval for modifications to the statistical analysis plan used to evaluate clinical data for Deramiocel. Plaintiffs allege that the company’s failure to disclose this lack of consensus rendered its public statements materially misleading, resulting in financial harm to investors.
In section Releases
Investors Target Capricor Therapeutics in Securities Class Action
The DJS Law Group has initiated a class action lawsuit against Capricor Therapeutics, alleging the company misled shareholders regarding the clinical development of its drug, Deramiocel. The complaint focuses on unauthorized statistical adjustments made prior to the firm's Biologics License Application submission to federal regulators.
Shareholders seeking to participate in the litigation or discuss potential lead plaintiff appointments must act before the September 28, 2026 deadline. Participation does not require an appointment as a lead plaintiff to recover losses. The legal action asserts violations of the Securities Exchange Act of 1934, specifically targeting the accuracy of disclosures provided to the market during the specified period.
Comments (0)
No comments yet. Be the first!